We ensure project stability for your study with a global turnover rate of just 6.68% among our tenured cell & gene therapy experts.

CRISPR is nothing short of a revolutionary advancement in science. Never before have researchers had such a precise tool with which to make controlled changes to genetic material — in plants, animals, and humans. This discovery has fueled the imaginations of researchers and innovators around the globe, and it has significantly expanded the potential for highly targeted advanced therapy medicinal products (ATMPs) in multiple therapeutic areas.
Cell and gene therapy (CGT) trials require careful orchestration between manufacturing and patient delivery. Our experts at Worldwide have built their careers in developing complex CGT programs across North America and Europe, and their experience spans all phases, various rare and non-rare indications, and all major treatment modalities.
CGT trials have unique challenges that require specialized personnel to optimize logistics, anticipate challenges, and ensure full regulatory compliance across multiple agencies. We deliver this while ensuring smooth and efficient handling of time-sensitive and temperature-sensitive critical materials.
At Worldwide, we understand the life-changing impact of novel CGT treatments requires nuanced regulatory knowledge and use our substantial expertise to optimize complex development programs with customized scientific, regulatory, medical, and operational strategies.
We partner with global patient communities to create achievable, sustainable trials that meet everyone’s needs, working tirelessly to improve the standard of care for patients with rare and complex diseases.
Executive Director, Therapeutic Strategy Lead, Rare Disease & Cellular and Genetic Medicines
Chief Medical and Scientific Officer
Executive Director, Global Regulatory Strategist
Executive Director, Site Activation & Regulatory Therapeutic Lead, Oncology
Senior Director, Project Management
Medical Director, Medical Affairs, Oncology & Rare Disease
Global Vice President, Therapeutic Strategy, Rare Disease and Oncology